Zacks.com on MSN1h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
A combination of two drugs that can block the growth of cancer cells has shown promising results in women with a form of ...
Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Iris Bincovich, CEO of Innocan Pharma, will be presenting at 2PM ET at the Lotus Suite West on October 30th. Members of the ...
Remain on track to initiate registrational THRIVE-3 trial in 1Q’ 2025NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.
Oregon decriminalized hard drugs in 2021 and recriminalized them last month. A new analysis shows the laws likely had little ...
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.
TipRanks on MSN18h
CStone Pharmaceuticals Unveils Patent for Innovative Cancer TherapyCStone Pharmaceuticals (HK:2616) has released an update. CStone Pharmaceuticals has announced the publication of a patent for ...
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Professor Susana Banerjee, from the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research said the findings were ‘significant’.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback